drugset / Trial / NCT06581419
A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
Phase I: To evaluate the safety, tolerance and effectiveness of IAP0971 for the treatment of advanced malignant tumors. Phase II: Evaluation of IAP0971 therapy driver negative and PD-L1 positive (TPS≥50%) The initial treatment is effective in subjects with advanced or metastatic non-small cell lung cancer.
Timeline
- Start
- 2024-12-31
- Primary completion
- 2029-08-01
- Completion
- 2029-08-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IAP0971 | Unknown | 0.0005 mg/kg | — |
| Subject | IAP0971 | Unknown | 18 mg/kg | — |